Investment Thesis
Hepion Pharmaceuticals is a pre-revenue pharmaceutical company with severe operational losses and negative profitability metrics, burning cash at an unsustainable rate despite holding adequate liquidity. The company lacks revenue generation capability while incurring significant operating expenses, resulting in negative ROE of -310% and operating cash flow burn of -3.3M annually. Without demonstrated clinical progress, revenue generation, or clear path to profitability, the company represents extremely high risk.
Strengths
- Strong liquidity position with 10.25x current ratio and $1.8M cash reserves relative to $3.1M total assets
- Minimal debt burden with debt-to-equity ratio of only 0.07x, reducing financial distress risk
- Low absolute liabilities at $402.4K provide operational flexibility
Risks
- Complete absence of revenue ($0.00) indicates pre-commercial stage with unproven business model
- Severe cash burn of -$3.3M in operating activities will deplete available cash within 7 months at current burn rate
- Catastrophic profitability metrics including -310% ROE, -269% ROA, and -$8.3M net loss demonstrate inability to generate value
- No insider buying activity in last 90 days suggests lack of confidence from management
- Operating losses of -$4.2M with zero offsetting revenue indicates excessive operating expenses relative to stage
Key Metrics to Watch
- Clinical trial progress and regulatory milestones toward revenue-generating assets
- Monthly operating cash burn rate and runway until capital depletion
- Achievement of first revenue milestone or partnership announcement
Financial Metrics
Revenue
0.0
Net Income
-8.3M
EPS (Diluted)
$-0.88
Free Cash Flow
-3.3M
Total Assets
3.1M
Cash
1.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-310.3%
ROA
-269.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
10.25x
Quick Ratio
10.25x
Debt/Equity
0.07x
Debt/Assets
13.1%
Interest Coverage
-957.39x
Long-term Debt
176.6K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T04:16:11.651217 |
Data as of: 2025-12-31 |
Powered by Claude AI